News & Updates

The final results of the CLL14 trial validate the long-term efficacy of 1-year fixed-duration venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia (CLL) and co-existing conditions.

Updates from the GARNET trial underpin dostarlimab monotherapy as a meaningful treatment option for women with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) advanced/recurrent endometrial cancer (A/R EC) who progressed after prior platinum therapy.

A novel oral formulation of paclitaxel, DHP107, is noninferior to weekly intravenous (IV) paclitaxel in the treatment of HER2-negative recurrent or metastatic breast cancer, as shown by the results of the phase III OPTIMAL study.

In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).

A fixed-dose combination of the novel amylin receptor agonist cagrilintide and the approved GLP-1 receptor agonist semaglutide (CagriSema) yields better HbA_1c control and weight loss in patients with type 2 diabetes (T2D) than either therapy alone or placebo in three phase III trials from the global REIMAGINE programme presented at ADA 2026. The benefits also extend to patients on insulin therapy.

A pooled analysis of data from the phase II KARDIA 2 and 3 studies shows the blood pressure (BP)-lowering potential of zilebesiran, an investigational, long-acting RNA interference therapeutic, when added to a renin–angiotensin–aldosterone system inhibitor (RAASi) in patients with hypertension (HTN).